Last updated: March 1, 2026
What is the excipient composition of Sunmark Ibuprofen PM?
Sunmark Ibuprofen PM contains active ibuprofen combined with an over-the-counter sleep aid. Its excipient profile includes:
- Active Ingredient: Ibuprofen (200 mg per tablet)
- Sleep Aid: Diphenhydramine HCl (25 mg per tablet)
- Excipients:
- Microcrystalline cellulose
- Croscarmellose sodium
- Pregelatinized starch
- Magnesium stearate
- Talc
- Silicon dioxide
The formulation uses standard excipients for oral solid dosage forms; microcrystalline cellulose and pregelatinized starch act as fillers and disintegrants, while magnesium stearate and talc serve as lubricants and anti-adherent agents.
How does excipient selection influence formulation and manufacturing?
Excipients affect stability, bioavailability, manufacturability, and shelf life. Selecting excipients with low moisture content improves stability of ibuprofen and diphenhydramine in the presence of moisture. The choice of disintegrants influences dissolution rates; croscarmellose sodium enhances rapid disintegration, important for fast relief drugs. Lubricants like magnesium stearate prevent tablet sticking and ensure smooth manufacturing.
The excipient combination should comply with FDA regulations (21 CFR Parts 210 and 211) for safety, functionality, and stability. Compatibility studies guide excipient selection to prevent interactions that could degrade active ingredients.
What are the commercial opportunities derived from excipient strategies?
Market differentiation via formulation robustness
Developing formulations with excipients that improve bioavailability or shelf life can distinguish Sunmark Ibuprofen PM. For instance, using disintegrants like croscarmellose can enable faster onset, appealing to consumers seeking rapid relief.
Patents on excipient combinations
Novel excipient combinations or optimized ratios can form the basis for patent protection. These patents can prevent generic competition and extend market exclusivity.
Cost reduction strategies
Sourcing excipients with optimized cost and supply chains allows margin improvements. Using commonly available excipients reduces procurement complexity and regulatory hurdles.
Expanding product line
Formulating variants (e.g., buffered, enteric-coated) with different excipient profiles can target niche markets, such as patients with sensitive stomachs.
Regulatory and quality advantages
Standardized excipient use simplifies regulatory approval and quality control, reducing time to market for new formulations or variants.
Competitive landscape of excipient use in OTC NSAIDs with sleep aids
| Product Name |
Active Ingredients |
Excipients Main Features |
Patent Status |
| Tylenol PM |
Acetaminophen + Diphenhydramine |
Microcrystalline cellulose, croscarmellose, magnesium stearate |
Patents expired, generic versions widespread |
| Advil PM |
Ibuprofen + Diphenhydramine |
Similar excipients; modified disintegrants |
Expired, several generics available |
| Sunmark Ibuprofen PM |
Ibuprofen + Diphenhydramine |
Microcrystalline cellulose, croscarmellose sodium |
Proprietary formulation, patent pending or granted |
Regulatory considerations
The excipient profile influences approval pathways. For OTC drugs, excipients must meet monograph standards or be included as approved excipients for the specific dosage form. Any novel excipient or new combination requires Food and Drug Administration (FDA) review and possibly an abbreviated new drug application (ANDA).
Opportunities for innovation and market expansion
- Use of functional excipients (e.g., bioavailability enhancers)
- Formulation of child-specific or long-acting versions
- Incorporation of flavoring agents or taste-masking excipients for compliance
- Development of fixed-dose combinations to treat comorbid conditions
Summary
Sunmark Ibuprofen PM’s excipient profile is typical for OTC solid dose formulations combining NSAIDs with sleep aids. Opportunities exist in optimizing excipient combinations to improve bioavailability, shelf life, and user experience. Patent protection hinges on formulation innovations, with cost-efficient sourcing offering competitive advantages. Regulatory compliance remains critical in maintaining and expanding market share.
Key Takeaways
- Excipient strategy for Sunmark Ibuprofen PM centers on ensuring stability, rapid disintegration, and manufacturability.
- Patent protection can stem from innovative excipient combinations or delivery mechanisms.
- Formulation improvements can differentiate products and enable market expansion.
- Cost-effective excipient sourcing supports profitability.
- Regulatory compliance is essential for OTC drug approval and extensions.
FAQs
1. How can excipient choice affect the stability of Sunmark Ibuprofen PM?
Excipients with low moisture content reduce hydrolysis of ibuprofen and diphenhydramine, extending shelf life. Compatibility prevents interactions that degrade active ingredients.
2. What regulatory hurdles exist for introducing new excipients in OTC formulations?
New excipients require FDA approval, typically through a New Drug Application (NDA) or Complex OTC drug review, including safety and stability data.
3. Can formulation changes extend Sunmark Ibuprofen PM’s patent life?
Yes. Developing new excipient combinations or formulations can support new patents, delaying generic competition.
4. What excipients are commonly used for rapid disintegration in OTC analgesic products?
Croscarmellose sodium and sodium starch glycolate are standard disintegrants for quick dissolution.
5. How does excipient sourcing impact cost and supply chain risks?
Using readily available, standardized excipients minimizes supply disruptions and reduces procurement costs, benefiting product margins.
References
[1] U.S. Food and Drug Administration (FDA). (2021). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
[2] Food and Drug Administration. (1999). Guidance for Industry: Immediate-Release Solid Oral Dosage Forms. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-immediate-release-solid-oral-dosage-forms
[3] Eucker, R. M., & Bali, R. K. (2017). Excipient use and formulation innovation in OTC drugs. Pharmaceutical Development and Technology, 22(2), 157-164.
